fda warning bpc-157 compounding pharmacies What's behind the push to make peptide therapies more readily available : NPR FDA panel on peptides will
Description
DSIP is administered in the evening before sleep, either intranasally or via subcutaneous injection
Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors

doi: 10.1074/jbc.M110.118620
Prostaglandins Leukot Essent Fatty Acids

Patients considering BPC-157 should be aware that using unlicensed substances carries inherent risks, including unknown side effects, lack of quality control, and potential interactions with prescribed medications
